Substance / Medication

Umbralisib

Overview

Active Ingredient
umbralisib
RxNorm CUI
2478439

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

11 trials linked to this intervention

11
Total Trials
9
Recruiting
1
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Clinical efficacy and safety of umbralisib, a dual PI3Kδ/CK1-ϵ inhibitor, in treatment of hematologic malignancies.
Zang Yunke, Cheng Hai-En, Sun Yanhua et al. · Front Oncol · 2025
PMID: 41568384Meta-AnalysisFull text (PMC)
Umbralisib-Induced Immune-Mediated Colitis: A Concerning Adverse Effect of the Novel PI3Kδ/CK1ε Inhibitor.
Bajaj Suryansh, Barrett Stevi M, Nakhleh Raouf E et al. · ACG Case Rep J · 2021
PMID: 34841000Case ReportFull text (PMC)
The evidence to date on umbralisib for the treatment of refractory marginal zone lymphoma and follicular lymphoma.
Schweitzer Janelle, Hoffman Meghan, Graf Solomon A · Expert Opin Pharmacother · 2022
PMID: 35209784Review
Long-term results of a phase 1/1b study of ibrutinib plus umbralisib for relapsed/refractory chronic lymphocytic leukemia.
Ryan Christine E, Ren Yue, Tyekucheva Svitlana et al. · Hemasphere · 2025
PMID: 39816532OtherFull text (PMC)
FDA Evaluating Possible Serious Risks From Umbralisib.
Aschenbrenner Diane S · Am J Nurs · 2022
PMID: 35617560Other
Phase 2 trial of umbralisib, ublituximab, and venetoclax in patients with relapsed/refractory mantle cell lymphoma.
Wallace Danielle S, Rowland Chris, Hill Brian T et al. · Leuk Lymphoma · 2023
PMID: 37341984Trial

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Umbralisib (substance)
SNOMED CT
1148656009
UMLS CUI
C4682392
RxNorm CUI
2478439

Clinical Data

This intervention maps to 6 entities in the Ltrl knowledge graph.

6
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
11
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.